Apogee Therapeutics (APGE) Competitors $38.33 +1.09 (+2.93%) Closing price 08/5/2025 04:00 PM EasternExtended Trading$91.88 +53.55 (+139.71%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock APGE vs. RGC, ELAN, RVMD, GRFS, TGTX, NUVL, CRSP, RYTM, LNTH, and AXSMShould you be buying Apogee Therapeutics stock or one of its competitors? The main competitors of Apogee Therapeutics include Regencell Bioscience (RGC), Elanco Animal Health (ELAN), Revolution Medicines (RVMD), Grifols (GRFS), TG Therapeutics (TGTX), Nuvalent (NUVL), CRISPR Therapeutics (CRSP), Rhythm Pharmaceuticals (RYTM), Lantheus (LNTH), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical products" industry. Apogee Therapeutics vs. Its Competitors Regencell Bioscience Elanco Animal Health Revolution Medicines Grifols TG Therapeutics Nuvalent CRISPR Therapeutics Rhythm Pharmaceuticals Lantheus Axsome Therapeutics Regencell Bioscience (NASDAQ:RGC) and Apogee Therapeutics (NASDAQ:APGE) are both pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, media sentiment, profitability, valuation and institutional ownership. Is RGC or APGE more profitable? Regencell Bioscience's return on equity of 0.00% beat Apogee Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Regencell BioscienceN/A N/A N/A Apogee Therapeutics N/A -28.35%-26.98% Which has more volatility & risk, RGC or APGE? Regencell Bioscience has a beta of 2.2, suggesting that its stock price is 120% more volatile than the S&P 500. Comparatively, Apogee Therapeutics has a beta of 1.43, suggesting that its stock price is 43% more volatile than the S&P 500. Does the media refer more to RGC or APGE? In the previous week, Apogee Therapeutics had 5 more articles in the media than Regencell Bioscience. MarketBeat recorded 6 mentions for Apogee Therapeutics and 1 mentions for Regencell Bioscience. Apogee Therapeutics' average media sentiment score of 1.17 beat Regencell Bioscience's score of 0.00 indicating that Apogee Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regencell Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Apogee Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend RGC or APGE? Apogee Therapeutics has a consensus target price of $99.00, indicating a potential upside of 158.28%. Given Apogee Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Apogee Therapeutics is more favorable than Regencell Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regencell Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Apogee Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher valuation and earnings, RGC or APGE? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRegencell BioscienceN/AN/A-$4.30MN/AN/AApogee TherapeuticsN/AN/A-$182.15M-$3.60-10.65 Do institutionals & insiders have more ownership in RGC or APGE? 0.1% of Regencell Bioscience shares are held by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are held by institutional investors. 42.8% of Apogee Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. SummaryApogee Therapeutics beats Regencell Bioscience on 7 of the 11 factors compared between the two stocks. Get Apogee Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APGE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding APGE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APGE vs. The Competition Export to ExcelMetricApogee TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.71B$3.07B$5.59B$9.53BDividend YieldN/A2.41%4.73%4.14%P/E Ratio-10.6517.5328.9123.88Price / SalesN/A313.17448.7998.82Price / CashN/A42.6035.6858.35Price / Book2.417.828.165.60Net Income-$182.15M-$54.52M$3.25B$265.26M7 Day Performance1.91%2.86%1.15%-0.14%1 Month Performance-19.39%17.29%8.25%6.08%1 Year Performance-8.19%13.27%29.18%24.22% Apogee Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APGEApogee Therapeutics2.6648 of 5 stars$38.33+2.9%$99.00+158.3%-6.3%$1.71BN/A-10.6591Positive NewsUpcoming EarningsRGCRegencell Bioscience0.0414 of 5 stars$13.80-8.3%N/AN/A$7.44BN/A0.0010Positive NewsELANElanco Animal Health3.814 of 5 stars$14.59-2.2%$16.17+10.8%+20.1%$7.41B$4.43B19.729,000Positive NewsUpcoming EarningsRVMDRevolution Medicines4.5128 of 5 stars$37.26-1.7%$68.91+84.9%-9.6%$7.06B$11.58M-9.32250GRFSGrifols3.38 of 5 stars$10.09-0.1%$10.30+2.1%+46.2%$6.94B$7.81B8.6223,822Dividend AnnouncementTGTXTG Therapeutics4.0474 of 5 stars$35.99-2.5%$43.80+21.7%+65.0%$5.86B$329M149.96290Trending NewsEarnings ReportOptions VolumeNUVLNuvalent3.3594 of 5 stars$81.94+0.7%$119.60+46.0%+9.6%$5.85BN/A-18.6740Positive NewsCRSPCRISPR Therapeutics3.5201 of 5 stars$63.75-1.6%$71.31+11.9%+11.9%$5.59B$37.31M-14.10460Trending NewsEarnings ReportAnalyst ForecastRYTMRhythm Pharmaceuticals3.4303 of 5 stars$85.68-0.9%$91.93+7.3%+101.2%$5.50B$130.13M-30.49140Earnings ReportLNTHLantheus4.6873 of 5 stars$72.41-0.7%$131.20+81.2%-26.7%$5.05B$1.53B20.57700Positive NewsAXSMAxsome Therapeutics4.8537 of 5 stars$100.39-0.4%$172.33+71.7%+24.5%$4.96B$385.69M-17.40380Trending NewsEarnings ReportAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies RGC Competitors ELAN Competitors RVMD Competitors GRFS Competitors TGTX Competitors NUVL Competitors CRSP Competitors RYTM Competitors LNTH Competitors AXSM Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:APGE) was last updated on 8/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored[Warning] Buffett Indicator hits new All-Time-HighWarren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullis...Golden Portfolio | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredStrange twist to Bitcoin’s rallyThe #1 crypto to buy today Better than Bitcoin? (top crypto for less than $1) Over the past 15 years, B...Stansberry Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apogee Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apogee Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
